Abstract:During a 3 year period, seventy patients aged 53 +/- 16 years with a total of 73 arrhythmias were treated over a mean period of 6.8 months (maximum 27 months) with oral propafenone, the usual dose being 900 mg/day. The study covered the whole spectrum of cardiac arrhythmias (32 supraventricular, 41 ventricular), and their relation to the autonomic nervous system. The efficacy was scored from 1 (no effect) to 5 (complete control) as judged by the clinical response, the results of Holter monitoring (175 control and 133 test recordings on therapy), and a comparison was made between the effects of propafenone and other antiarrhythmics: quinidine-like drugs, beta-blockers and amiodarone. With respect to supraventricular arrhythmias: 9 cases of vagally-induced atrial flutter and fibrillation were unaffected by propafenone (mean score = 1.1). On the other hand, the drug was very effective (mean score = 4.1) in 8 cases of adrenergic atrial arrhythmias. In 12 arrhythmias with more varied mechanisms (extrasystoles, tachysystole, paroxysmal atrial fibrillation) an intermediate score was obtained (2.8). Three cases of resistant junctional tachycardia due to reentry were improved. At ventricular level, 5 cases of extrasystole sensitive to quinidine were also improved by propafenone (4.6); the difference was more clearcut in 8 cases of benign idiopathic tachycardia (propafenone: 4.1, and quinidine: 2.4). This was more marked in 13 cases of more severe arrhythmia in diseased hearts in which the effect of propafenone (4.1) was superior even to that of amiodarone. However, propafenone was less effective (3.3) than amiodarone in 4 cases of severe polymorphic idiopathic ventricular tachycardia closely related to the autonomic nervous system. The antiarrhythmic effect of propafenone was appreciable in 10 cases of resistant post-infarction ventricular tachycardia, eventually in association with amiodarone. Slowing of the sinus rhythm (-11.6%) with no change in the day/night ratio was due to beta-inhibition. However, in toxic doses this may progress to sinoatrial block (9 cases). A lengthening of the PR interval and duration of QRS was common, but this was not complicated by torsade de pointes, one case of which was successfully treated by propafenone. Secondary gastro-intestinal effects and vertigo were rarely severe enough to warrant stopping therapy. In conclusion, these results show that the introduction of propafenone is a valuable therapeutic advance in the treatment of arrhythmias, especially in those with a favoring adrenergic mechanism.

Effect of Oral Propafenone on Reversing Paroxysmal Atrial Fibrillation with No Rheumatic Disease

Comparison of Converting Efficacy and Safety of Intravenous Ibutilide and Propafenone in Chinese Patients with Atrial Fibrillation and Atrial Flutter

[Efficacy and Safety of Ibutilide for Conversion of Atrial Fibrillation/flutter].

Inducibility and ablation of atrial fibrillation from non-pulmonary vein foci in patients with paroxysmal atrial fibrillation

Intravenous Propafenone and Amiodarone in the Treatment of Paroxysmal Atrial Fibrillation Effect Comparison

Propafenone in the Prevention of Atrial Fibrillation After Pulmonary Resections

European experience with the antiarrhythmic efficacy of propafenone for supraventricular and ventricular arrhythmias

[Anti-arrhythmic effect of oral propafenone. Apropos of 70 cases]

Efficacy and speed of conversion of recent onset atrial fibrillation using oral propafenone versus parenteral amiodarone: A randomized controlled comparative study

Oral Amiodarone In Blank Period Affects Mmp-9 And Timp-1 Level In Post-Ablation Paroxymal Atrial Fibrillation Patients

Comparison of Propafenone Vs Moricizine for the Treatment of Paroxysmal Atrial Fibrillation

Ultrasound Ablation of Pulmonary Veins for Treatment of Paroxysmal Atrial Fibrillation

The Effects of Propafenone on Postoperative Atrial Fibrillation in Adult Patients Undergoing Cardiac Surgery: A Meta‐Analysis of Randomized Controlled Trials

Effect of Different Anti-Arrhythmic Agents on Patients with Paroxysmal Atrial Fibrillation and Congestive Heart Failure

Randomized double-blind study comparing the efficacy and safety between antazoline and propafenone for conversion of paroxysmal atrial fibrillation to sinus rhythm (AnProAF study)

Cardiac electrophysiologic effects of intravenous ibutilide compared with intravenous propafenone in patients with rencent-onset atrial fibrilation

Evaluation of Radiofrequency Catheter Ablation in Treating Patients with Paroxysmal Atrial Fibrillation

Analysis on efficacy of amiodarone combined with valsartan treating paroxysmal atrial fibrillation

Effect of annular pulmonary vein electrical isolation method on reversal and remodeling cardiomyopathic patients with paroxysmal atrial fibrillation

The effect of radiofrequency catheter ablation on cardiac reverse remodeling in cardiomyopathy patients with paroxysmal atrial fibrillation

[Efficacy of amiodarone versus propafenone in the prevention of rhythm disorders in patients after aortocoronary bypass surgery]